Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.37 |
| ▸ | BCL2 | P10415 | 3/20 | 0.37 |
| ▸ | PPARA | Q07869 | 4/20 | 0.35 |
| ▸ | PPARG | P37231 | 4/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | BAD | Q92934 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4988180 | 0.86 | DUT (0.47) | DUTMCL1BCL2PPARAPPARG | |
| SCHEMBL4989610 | 0.84 | DUT (0.48) | DUTMCL1BCL2PPARAPPARG | |
| SCHEMBL2263579 | 0.84 | DUT (0.52) | DUTMCL1PPARAPPARGCYP24A1 | |
| SCHEMBL6030279 | 0.83 | DUT (0.51) | DUTMCL1BCL2PPARAPPARG | |
| SCHEMBL2263898 | 0.81 | DUT (0.52) | DUTCYP24A1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6029849 | 0.78 | CDK4 (0.57) | DUTHTR2C | |
| SCHEMBL20348541 | 0.77 | HTR2C (0.46) | DUTMCL1CYP24A1HTR2CALDH1A1 | |
| SCHEMBL2259836 | 0.77 | DUT (0.47) | DUTMCL1BCL2PPARABAD | |
| SCHEMBL2262948 | 0.76 | DUT (0.42) | DUTHTR2CSMN1; SMN2 | |
| SCHEMBL20337987 | 0.76 | HTR2C (0.53) | DUTMCL1PPARAPPARGHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109229-B2 | Methods and compounds for treating proliferative diseases | ELI LILLY AND COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1325011-B1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | LILLY CO ELI (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040048915-A1 | Methods and compounds for treating proliferative diseases | ENGLER THOMAS ALBERT (US) | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048915-A1 | Methods and compounds for treating proliferative diseases | CDK4, CCNI, CCNA1 | DUT 175/4885MCL1 131/4885BCL2 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.